Journal article
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
- Abstract:
-
AIMS/HYPOTHESIS: The aim of the study was to examine the 48 month outcome of treating recent-onset type 1 diabetic patients for 6 days with humanised CD3-antibody, ChAglyCD3. METHODS: Eighty patients, aged 12-39 years, were recruited for a phase 2 multicentre trial and randomised to placebo (n=40) or ChAglyCD3 (n=40) treatment by a third party member; participants and care-givers were blinded. The change in insulin dose (U kg(-1)day(-1)) over 48 months was chosen as primary endpoint and compa...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Diabetologia
- Volume:
- 53
- Issue:
- 4
- Pages:
- 614-623
- Publication date:
- 2010-04-01
- DOI:
- EISSN:
-
1432-0428
- ISSN:
-
0012-186X
- Source identifiers:
-
51975
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:51975
- UUID:
-
uuid:94e17191-c0b8-4e2c-82be-0717d29fc23b
- Local pid:
- pubs:51975
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2010
If you are the owner of this record, you can report an update to it here: Report update to this record